Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
about
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and diseaseMolecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand BreaksUsing large-scale genomics data to identify driver mutations in lung cancer: methods and challengesMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularEtiologic field effect: reappraisal of the field effect concept in cancer predisposition and progressionDiscovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiologyCIViC databaseCancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerA consensus statement on the gender perspective in lung cancer.Rationale for RAS mutation-tailored therapies.Reconstructing targetable pathways in lung cancer by integrating diverse omics dataClinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularUsing multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.Proceedings of the second international molecular pathological epidemiology (MPE) meetingA hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancerClinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations.Notch1 mutations are drivers of oral tumorigenesisMAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking statusPrognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasThe mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order.Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung CancerEGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and PrognosisReal-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors.An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients
P2860
Q24289344-BC6D5BAD-461A-4803-8638-A7BABC1488EEQ26781994-15DC244F-3918-48DB-B8AA-5F4EA7F233F0Q26800833-99A76046-DC9D-4C7F-9261-F66668372173Q26828860-C2EF7349-B223-4E73-8788-688EA18C436CQ26852716-55CEFFE9-252F-4DEC-BEFA-599D71F6A9A7Q27011884-22868B49-FF89-4440-8998-BDB07B82BAC4Q27612411-06B5C13B-5400-4727-8FF9-7C5B5AEBFD19Q29615679-8E890279-9A8B-4BC9-8B55-2ABEF77E3945Q30240700-44F238B5-D105-4DBD-B0D2-A8F5BBB6A746Q30244673-71C056EE-B87D-4BF3-B0E9-CD3E2BEEAE70Q30679547-98461990-4345-4C4C-A071-6D13DEBCEE96Q33571227-91EF2626-AB99-44CC-9D5F-0AF54C35BFEAQ33633715-2601BC57-97D7-4679-95DF-F2A402FE2C71Q33682941-0142DC3C-9C67-4D34-99DC-ADC747F1AD58Q33690682-C401FDDC-7DAA-45E4-8C06-499981FCBF8FQ33793611-69B8D5FD-F6CD-4F17-8779-01253C3C9A87Q33799673-3C1525ED-A4DF-4577-A903-CB37E1B04A18Q33878516-4499D0BD-C536-4E1A-A0E6-B7D9DA91443DQ34016833-5FC5A4B6-E230-4CF3-8251-664266C453A2Q34159011-011348C2-0CB2-4368-9A6D-9B56A0749062Q34175045-F3CC1E0A-558F-4FEC-B351-E7384CF57A28Q34347975-1FC28DC6-42D4-4132-8C42-C4331DDE1218Q34475686-9D19ED6E-9ACF-4B63-A734-E32E6C77DD2FQ34518559-DADB257D-4E56-4D5B-8DAB-89F8F16A4251Q34952066-568FE154-EF8E-4AE5-BD95-386D31E926F3Q35007886-A6A9B688-9D85-455A-8096-25BB3843F99BQ35016912-20A2A3E3-AF69-4EAD-97BF-5867546096BDQ35200585-101916DB-C152-47D6-9FE9-8DA198BE4D34Q35251675-80CBF6D6-1DD5-4B90-AFC3-3DFCA218C04CQ35462978-1C18164B-5BDB-44CE-84C5-42041379DD2FQ35541778-3417A881-47FB-4E9E-B05A-DCAE978871D7Q35637007-F8ACAE95-B0F0-4639-AE6C-5FE3BAFE03BDQ35775729-F0EBEF32-299E-431C-B6C5-04084D826A2AQ35782746-A1A56442-6892-42C6-AB4C-CE72E3997F4EQ35967703-EA43B7C0-4F7E-47F1-9544-61149D504B3FQ36044399-35CA4252-4C0C-4D0B-AAD7-25C052E41194Q36050294-BF53D39D-0967-48A3-95C8-1221C9E23089Q36100833-4BAA1CA4-3561-4170-9235-204741E32EAEQ36228469-48FB0C3D-D656-495C-B86D-C63148975F34Q36330709-F1C3B991-7335-48B6-A11F-4A7ACEE66ED5
P2860
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@ast
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@en
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@nl
type
label
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@ast
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@en
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@nl
altLabel
Molecular Epidemiology of EGFR ...... ng-Related KRAS-Mutant Cancers
@en
prefLabel
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@ast
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@en
Molecular epidemiology of EGFR ...... ng-related KRAS-mutant cancers
@nl
P2093
P2860
P3181
P1476
Molecular epidemiology of EGFR ...... g-related KRAS-mutant cancers.
@en
P2093
Daphne C Ang
Edyta B Brzostowski
Gregory J Riely
Mark G Kris
Maureen F Zakowski
Melissa L Johnson
Paul K Paik
Ronglai Shen
Sandra P D'Angelo
Snjezana Dogan
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-11-3265
P407
P50
P577
2012-11-15T00:00:00Z